Physician profile
Andre C King
NPI 1588868426
$1,272.19
in general payments reported to CMS, 2019-2025
12 companies · $94.44 in 2025
The $94.44 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $312 · 2020: $127 · 2024: $739 · 2025: $94.44.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $624 · Food and Beverage: $209.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $624.01 |
| Food and Beverage | $209.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Procept Biorobotics Corporation | $812.82 | 2024-2025 | Aquabeam System |
| Janssen Biotech, INC. | $219.83 | 2019-2020 | |
| Astellas Pharma US INC | $42.85 | 2019 | |
| Boston Scientific Corporation | $37.41 | 2019 | |
| Antares Pharma, INC. | $30.18 | 2019-2020 | |
| Pfizer INC. | $26.00 | 2019-2020 | |
| Neotract INC. | $24.82 | 2019 | |
| Smith+Nephew, INC. | $20.20 | 2024 | Stravix |
| Dendreon Pharmaceuticals LLC | $18.61 | 2019 | |
| C. R. Bard, INC. & Subsidiaries | $14.71 | 2019 | |
| Amag Pharmaceuticals, INC. | $13.16 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andre King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.